Looking for a new broker?
Cue Biopharma, Inc. stock is up 23.96% since 30 days ago. The next earnings date is Mar 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 83.33% of the previous 5 November’s closed higher than October. 100% of analysts rate it a buy.
Cue Biopharma, Inc. develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.
